Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Metrics to compare | CYBN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYBNPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −3.1x | −0.6x | |
PEG Ratio | −0.15 | −0.04 | 0.00 | |
Price/Book | 1.1x | 0.3x | 2.6x | |
Price / LTM Sales | - | 2.0x | 3.1x | |
Upside (Analyst Target) | - | 126.4% | 52.8% | |
Fair Value Upside | Unlock | 26.3% | 8.4% | Unlock |